DBV Technologies (DBVT) Cost of Revenue (2020 - 2026)
DBV Technologies (DBVT) reported Cost of Revenue of $4.8 million for Q1 2026, up 1500.0% year-over-year from $300000.0 in Q1 2025, and up 251.91% quarter-over-quarter from $1.4 million in Q4 2025.
DBV Technologies (DBVT) Cost of Revenue (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Cost of Revenue data on file, last reported at $4.8 million in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $4.8 million, up 1500.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.8 million (up 252.61% YoY), and the FY2025 annual result was $3.2 million, up 21.17% from the prior year.
- Cost of Revenue improved to $4.8 million in Q1 2026 per DBVT's latest filing, from $1.4 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $4.8 million in Q1 2026 and troughed at -$51000.0 in Q4 2022.
- A 5-year average of $868647.1 and a median of $519000.0 in 2024 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2023 and 2025: Cost of Revenue soared 1717.65% in 2023, then slumped 60.42% in 2025.
- A 5-year view of Cost of Revenue shows it stood at -$51000.0 in 2022, then soared by 1717.65% to $825000.0 in 2023, then slumped by 52.0% to $396000.0 in 2024, then surged by 244.44% to $1.4 million in 2025, then surged by 251.91% to $4.8 million in 2026.
- Business Quant data shows DBVT's Cost of Revenue at $4.8 million in Q1 2026, $1.4 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 4.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.80 Mn |
| Mar 31, 2026 | 4.80 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 419,000.00 |
| Jun 30, 2025 | 419,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Dec 31, 2024 | 396,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Jun 30, 2024 | 986,000.00 |
| Jun 30, 2024 | 986,000.00 |
| Mar 31, 2024 | 758,000.00 |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | 825,000.00 |
| Dec 31, 2023 | 825,000.00 |